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This Materials Transfer Agreement is made on this day, of 30 October 2009 by and between:  
 
The Faculty of Medicine, Diponegoro University, an Indonesian Research institution existing 
under the laws of the Republic of Indonesia, having its registered office at Jl. Dr. Sutomo No. 18, 
Semarang, Central Java Province, Indonesia (hereinafter referred to as “First Party”), 
represented by Prof. Sultana M. H. Faradz, MD, PhD, in this matter acting in her capacity as the 
Director of The Center For Biomedical Research, Faculty of Medicine, Diponegoro University. 
 
Radboud University Nijmegen Medical Centre, a research institution existing under the laws of 
Dutch Government having its registered office at Nijmegen, The Netherlands, [Tel] 
+31.243614017,  [Fax]  +31.243668752, represented by Prof. Frans P.M. Cremers, head 
Division of Molecular Genetics of the Department of Human Genetics, in this matter acting in 




dr. Kentar Arimadyo Sulakso SpM, domiciled at Jl Bukit Barisan C1 no 9, Perum Bukit Permata 
Puri, Ngaliyan, Semarang, Central Java Province, Indonesia, Tel: +62-24-7629003 and Dr. Rob 
W.J. Collin (hereinafter referred to as “Scientists”). 
 
(The Recipient and Scientists shall collectively hereinafter referred to as “Second Party”) 
 
 
In consideration of the Recipient’s and the Scientist’s covenant and premises contained herein, 
the First Party agrees to provide the Materials to the Second Party for the sole purpose of the 
study and for specific assays (Research Plan/Protocol) described in Appendix B, which shall be 




In this Agreement, definitions that are used are as the following meaning: 
 
Materials : means Original Materials, Progeny, and Unmodified 
Derivatives of the biological specimens and or data described in 
Appendix A.  
 
Original Materials  : means substances as described in the Appendix A. 
 
Progeny : unmodified genetic descendant from the Materials. 
 
Unmodified Derivatives : substances created by the Recipient which constitute an 
unmodified functional subunit or product expressed by the 
Original Materials. 
 
Modifications : substances created by the Recipient which contain and/or 
incorporate the Materials. 
 
Research Plan/Protocol  : study and for specific assays and research to be under taken as 
described in the Appendix B. 
 
2. OWNERSHIP OF MATERIALS 
The Second Party acknowledges that rights, title and interest of the Original Materials are the 
property of the First Party and the First Party shall retain ownership and the Modifications. 
3. USE OF MATERIALS 
The Second Party undertakes to use the Materials and Modifications, solely for the purpose 
of Research Plan/Protocol as further described in the Appendix B (The research Proposal); 
and in accordance with the terms of this Agreement and laws, and regulation. The Second 
Party will not undertake to transfer, distribute, release, or disclose by any means, either 
intentional or accidental, the Materials or Modifications except as expressly stated in 
Appendix B for the sole purpose of the Research Plan/Protocol under the supervision of the 
Scientist; and also not to use the Materials or Modifications for any purpose other than as 
expressly stated in Appendix B/non-commercial research. 
4. THE RESEARCH PLAN/ PROTOCOL  
The Research Plan/Protocol shall be developed together by the Parties in providing best effort 
to conduct the research, the tests, and the experiments related to the Research Plan/Protocol 
within the jurisdiction of the Republic of Indonesia The Second party shall send in 
confidence, to the First Party any and all data, records, and results derived from the Materials 
and Research Plan, including detailed records of direct use of the Materials. 
 
5. INTELLECTUAL PROPERTY RIGHTS 
The Second Party acknowledges that the Materials or Modifications are or maybe the subject 
of patent application. Nothing in this Agreement grants any implied or express license or 
right under any patents or in any know-how or trade secrets other proprietary rights to use the 
Materials or Modifications or any product or process related thereto for profit-making or 
commercial purposes, including but not limited to, production, sale, screening or drug design. 
The Recipient agrees to negotiate in good faith a license with the First Party prior to making 
any such profit-making or commercial use. The First Party shall have no obligation to grant 
such license to the Recipient, and may grant exclusive or non-exclusive licenses to others 
who may be investigating uses of the Materials or Modifications. 
 
6. RETURN OF MATERIALS AND MODIFICATIONS 
The First Party may request to the Second Party to return any and all unused Materials, 




The use of any data, results, or concepts (hereinafter referred to as “Outputs”), derived from 
use of the Materials in presentations, abstracts, publications (both peer-reviewed and not 
peer-reviewed), grants, or other means of disseminations by the Recipient and/or Scientist 
shall require written consent from the First Party. In the event that the Second Party wishes to 
use Outputs for dissemination of any kind as described above, the Second Party shall provide 
a written request along with a copy of the presentation, abstract, manuscript, grant or other 
medium to the First party prior to any requested date of dissemination. The inclusion of the 
First Party in the Outputs will be as author or co-author, shall be described in details in the 
Research Plan/Protocol. The First Party agrees that it will acknowledge the Second Party’s 
publications, as academically and scientifically appropriate 
 
8. CONFIDENTIALITY 
The Second Party shall treat in confidence any information relating to the Materials and/or 
Modifications saved.  
 
9. DISCLAIMER OF WARRANTY 
The First Party makes no representations, conditions or warranties either  express or implied 
with respect to any of the Materials or Modifications and disclaims any implied warranty, 
condition or representation that the Materials or Modifications. The First party shall not be 
liable for loss whether direct, consequential, incidental or special (and whether arising out of 
contract or tort) which the Recipient or the Scientist may suffer arising from the use, 




The Second Party hereby jointly and severally agree and undertake to indemnify, hold 
harmless and defend the First Party against any and all claims, actions, damages, liabilities, 
loss whatsoever (including all legal costs and expenses on a full indemnity basis) arising out 
of or resulting from directly, the possession, use and/or storage of any of the Materials and 
Modifications or by reason of any breach of the terms herein by the Recipient and/or the 
Scientist. The First Party should be liable for consequential or incidental damages arising 
from breach or breaches of this Agreement. No action, whether in contract or tort (including 
negligence) or otherwise arising out of or in connection with this Agreement may be brought 




This Agreement will terminate on the earliest of the following date: (a) on the completion of 
the implementation activities set forth in the Research Plan/Protocol as described in the 
Appendix B, or (b) on 30 (thirty) days’ written notice by either party to another. The First 
Party may terminate this agreement if it is of the view that the Recipient and/or the Scientist 
are in breach of any of the terms here of and such breach, if capable of being remedied, is 
not remedied by the Recipient or Scientist after 30 (thirty) day’s Notice by the First Party.  
 
12. ARBITRATION 
12.1 Failing such an amicable settlement, any and all disputes, controversies, and conflicts 
arising out of, or in connection with this Agreement, or its performance, shall be finally 
settled by arbitration in accordance with the Arbitration Rule of the International 
Chamber of Commerce (“ICC”), which rules are deemed to be incorporated by 
reference into this clause. The Arbitration proceedings shall take place in Jakarta and 
shall be conducted in English. 
 
12.2 The Parties agree that the Panel of Arbitrators shall consist of 3 (three) arbitrators. The 
First Party and the Second Party shall respectively have the right to appoint 1 (one) 
arbitrator and should one party fail to appoint its arbitrator in 14 (fourteen) days from 
the appointment of the first arbitrator, then such arbitrator shall be appointed by the 
ICC. The 2 (two) arbitrators so appointed shall jointly appoint the third arbitrator who 
will act as the Chairman of the Panel of Arbitrators. Should the 2 (two) arbitrators fail 
to appoint the third arbitrator in 14 (fourteen) days from the appointment of the second 






First Party: Prof. Dr. Sultana M.H. Faradz, MD, PhD, Center for Biomedical 
Research, Faculty of Medicine, Diponegoro University 
[Address]: Jl. Dr. Sutomo, No 14 Semarang, Central Java Province, Indonesia 
[Fax:] +62-24-8454714 
Second Party: 
The Recipient and Scientist:  
Prof. Dr. Frans P.M. Cremers, Department of Human Genetics, Radboud University 
Nijmegen Medical Centre, Nijmegen, the Netherlands,  
[Address]: Geert Grooteplein Zuid 8, 6525 GA Nijmegen 
[Tel] + 31.243614017  






Concentration of DNA control panel 
 




1 01/DS M 054060 351.5 104 01/Pras/05 V 054327 470 
2 02/HR M 054061 146.9 105 02/Pras/05 V 054328 1006 
3 03/D M 054062 266.2 106 03/Pras/05 V 054329 305 
4 04/AW V 054063 178.5 107 04/Pras/05 V 054330 153 
5 05/TJ V 054064 739.3 108 05/Pras/05 V 054331 274 
6 06/INF V 054065 199.7 109 06/Pras/05 V 054332 466 
7 07/M M 054066 393.6 110 07/Pras/05 V 054333 186 
8 08/SP M 054067 667.8 111 08/Pras/05 V 054334 653 
9 09/SG M 054068 509.7 112 09/Pras/05 V 054335 101 
10 10/ST M 054069 670.6 113 10/Pras/05 V 054336 80.6 
11 11/AR M 054070 357.2 114 42/Stock/05 V 054337 519 
12 12/MJ M 054071 643 115 43/Stock/05 V 054338 518 
13 13/JN M 054072 478 116 45/Stock/05 V 054339 620 
14 14/FY M 054073 132.6 117 14/Stock/05 M 054340 238 
15 15/NN V 054074 88.15 118 47/Stock/05 V 054341 354 
16 16/ARF M 054075 408.5 119 48/Stock/05 M 054342 789 
17 17/SW M 054076 316.1 120 49/Stock/05 M 054343 604 
18 18/NG V 054077 353 121 50/Stock/05 M 054344 487 
19 19/YK M 054078 519.4 122 53/Stock/05 M 054345 726 
20 20/WN M 054079 807.5 123 54/Stock/05 V 054346 687 
21 21/F V 054080 129.9 124 55/Stock/05 V 054347 367 
22 22/LW M 054081 360.4 125 56/Stock/05 V 054348 264 
23 23/B M 054082 467 126 57/Stock/05 V 054349 406 
24 24/ABD M 054083 369.1 127 58/Stock/05 V 054350 580 
25 25/AM M 054084 366.3 128 59/Stock/05 V 054351 178 
26 26/SB M 054085 301.2 129 61Stock/05 V 054352 281 
27 27/SK V 054086 242.2 130 64/Stock/05 V 054353 186 
28 28/WR V 054087 342.3 131 65/Stock/05 V 054354 362 
29 29/TH M 054088 136.2 132 67/Stock/05 V 054355 266 
30 30/HL V 054089 603.2 133 68/Stock/05 V 054356 212 
31 31/BH M 054090 278.9 134 69/Stock/05 V 054357 369 
32 32/NT M 054091 26.02 135 70/Stock/05 M 054358 169 
33 33/HM M 054092 217.3 136 71/Stock/05 M 054359 365 
34 34/KS M 054093 449 137 72/Stock/05 M 054360 254 
35 35/RB V 054094 325.1 138 73/Stock/05 M 054361 782 
36 36/MR V 054095 434.3 139 74/Stock/05 M 054362 140 
37 37/SR V 054096 45.3 140 75/Stock/05 M 054363 532 
38 38/HK V 054097 265 141 01/Stock/05 M 054364 1251 
39 39/SJ V 054098 93.67 142 02/Stock/05 V 054365 334 
40 40/SBD M 054099 324.9 143 03/Stock/05 V 054366 435 
41 41/SKR V 054100 130 144 04/Stock/05 V 054367 568 
42 42/RT V 054101 389.2 145 05/Stock/05 M 054368 216 
43 43/DM V 054102 448.3 146 17/Stock/05 M 054369 674 
44 44/PW M 054103 267.2 147 21/Stock/05 M 054370 246 
45 45/HS M 054104 400.3 148 26/Stock/05 M 054371 697 
46 46/ST V 054105 450.5 149 15/Stock/05 M 054372 367 
47 47/BW M 054106 483 150 13/Stock/05 M 054373 464 
48 48/AK M 054107 229.6 151 77/Stock/05 M 054374 334 
49 49/MU V 054108 199.9 152 79/Stock/05 V 054375 483 
50 50/SH M 054109 272.6 153 81/Stock/05 V 054376 603 
51 51/BP V 054110 225.2 154 82/Stock/05 V 054377 273.8 
52 52/EP V 054111 79.22 155 84/Stock/05 V 054378 165 
53 53/PSS V 054112 130.1 156 85/Stock/05 M 054379 455 
54 54/TA V 054113 114.5 157 01/CLH/08 M 054380 656 
55 55/SL V 054114 178.9 158 02/CLH/08 M 054381 427 
56 56/SI V 054115 186 159 03/CLH/08 M 054382 705 
57 57/PJ V 054116 274.2 160 04/CLH/08 M 054383 465 
58 58/SNT V 054117 159.8 161 05/CLH/08 M 054384 416 
59 59/SRJ V 054118 193.2 162 06/CLH/08 M 054385 443 
60 60/MYT V 054119 40.97 163 07/CLH/08 M 054386 277 
61 61/AYN V 054120 195 164 08/CLH/08 M 054387 835 
62 62/T V 054285 22.3 165 09/CLH/08 M 054388 426 
63 63/DU V 054286 15.05 166 10/CLH/08 M 054389 363 
64 64/SS V 054287 344.4 167 11/CLH/08 M 054390 132 
65 65/STR V 054288 201.7 168 12/CLH/08 V 054391 247 
66 66/PH M 054289 275.6 169 13/CLH/08 M 054392 165 
67 67/SNW M 054290 383.1 170 14/CLH/08 M 054393 355 
68 68/Pi V 054291 148.8 171 15/CLH/08 M 054394 184 
69 69/BSK M 054292 289.6 172 16/CLH/08 V 054395 398 
70 70/DD M 054293 232.4 173 17/CLH/08 V 054396 135 
71 71/HTT V 054294 182.2 174 18/CLH/08 V 054397 397 
72 72/ANT V 054295 355 175 19/CLH/08 V 054398 365 
73 73/PWT M 054296 369.2 176 01/CK/09 V 054399 544 
74 74/TTW V 054297 339.4 177 02/CK/09 V 054400 550 
75 75/SGT M 054298 199.4 178 03/CK/09 V 054401 263 
76 76/IDH V 054299 193.7 179 04/CK/09 V 054402 654 
77 77/ABW M 054300 193.3 180 05/CK/09 V 054403 188 
78 78/BHS M 054301 93.81 181 06/CK/09 V 054404 338 
79 79/TJO M 054302 108.6 182 07/CK/09 V 054405 272 
80 80/JRK M 054303 147.1 183 08/CK/09 V 054406 813 
81 81/SDY M 054304 99.1 184 09/CK/09 V 054407 212 
82 82/KNT M 054305 247 185 10/CK/09 V 054408 571 
83 83/THY V 054306 236.1 186 11/CK/09 V 054409 341 
84 84/HSO M 054307 327.2 187 12/CK/09 V 054410 361 
85 85/RAM V 054308 181.3 188 13/CK/09 M 054411 624 
86 86/STR M 054309 172.6 189 14/CK/09 M 054412 527 
87 87/RKD M 054310 115.2 190 15/CK/09 M 054413 476 
88 88/DSW V 054311 76.82 191 16/CK/09 M 054414 254 
89 89/UCY V 054312 121 192 17/CK/09 M 054415 353 
90 90/HBW M 054313 100 193 18/CK/09 M 054416 318 
91 91/SWN V 054314 218.2 194 19/CK/09 M 054417 431 
92 92/HDY M 054315 262 195 20/CK/09 M 054418 279 
93 93/SGT M 054316 219.8 196 21/CK/09 V 054419 450 
94 94/MKR M 054317 232.5 197 22/CK/09 M 054420 240 
95 95/FSW V 054318 135.8 198 23/CK/09 M 054421 512 
96 96/TSR V 054319 135.9 199 24/CK/09 M 054422 281 
97 97/AWN V 054320 147.8 200 25/CK/09 V 054423 223 
98 98/JRT V 054321 347.5 201 04/KTR/08 V 054424 954 
99 99/KSD M 054322 110.5 202 05/KTR/08 M 054425 867 
100 100/EDH V 054323 77.28 203 06/KTR/09 V 054426 774 
101 101/DWS V 054324 51.57 204 07/KTR/09 V 054427 862 
102 102/WWK V 054325 47.92 205 08/KTR/10 M 054428 394 
103 103/PWS V 054326 128.6 206 09/KTR/10 M 054429 512 
















JUDUL PENELITIAN     :  IDENTIFICATION OF GENETIC CAUSES OF RETINITIS 
PIGMENTOSA IN THE INDONESIAN POPULATION USING   
HIGH RESOLUTION HOMOZYGOSITY MAPPING                     
INSTANSI PELAKSANA   :    BAGIAN ILMU KESEHATAN MATA FK UNDIP/ RS Dr 
KARIADI SEMARANG DAN CEBIOR FK UNDIP 
 
PERSETUJUAN SETELAH PENJELASAN 




Bapak/Ibu akan kami ajak untuk berpartisipasi dalam penelitian ini.  
Bapak/ Ibu menderita gangguan penglihatan akibat adanya kelainan pada lapisan sel foto 
reseptor retina yang berfungsi untuk penglihatan. Penyakit ini dapat mengakibatkan kebutaan 
total pada stadium yang lanjut. Gejala awal penderita berupa rabun senja disertai adanya 
penyempitan lapang pandang penderita secara perlahan. Penyempitan lapang pandang ini 
bermula dari daerah perifer dan pada akhirnya juga mengenai daerah sentral yang berakhir pada 
kebutaan total. Penyakit ini diturunkan secara genetik melalui orang tua penderita. Adapun jenis 
penurunan sifatnya berupa automal dominan dimana terjadinya penyakit ini diperoleh dengan 
cukup adanya satu copy gen autosomal yang diperoleh dari salah satu  orang tuanya, autosomal 
resesif dimana penyakit ini diturunkan apabila didapat 2 copy gen autosomal yang termutasi dan 
diperoleh dari kedua orangtuanya dan X-linked apabila penyakit ini diperoleh dari mutasi gen 
yang diturunkan melalui kromosom sex X. Untuk kasus autosomal resesif kedua orang tua 
penderita mempunyai andil dalam penurunan sifat penyakit ini. 
Dengan diketahuinya sifat penurunan dan mutasi gen penyebab Retinitis Pigmentosa ini 
penderita mampu merencanakan masa depannya secara lebih bijaksana dan mantap. Misalnya 
bila ingin mencari pasangan ataupun ingin memiliki anak, dimana selama ini masih ada 
kekhawatiran tentang kemungkinan anaknya juga ikut terkena penyakit ini. Dengan mengetahui 
hal tersebut banyak pilihan yang bisa diperoleh untuk masa depan yang lebih baik. Jenis mutasi 
tertentu pada Retinitis Pigmentosa saat ini sudah dapat disembuhkan meski baru dilakukan di 
Negara maju. Dengan mengetahui jenis mutasi gen juga dapat mencegah terjadinya kerusakan 
photoreceptor lebih lanjut, dikarenakan jenis mutasi gen tertentu dengan pemberian suplemen 
vitamin A justru memperberat keadaan Retinitis pigmentosanya. 
Tindakan yang akan dialami Bapak/ Ibu : 
1. Kami akan memberikan pertanyaan mengenai gejala penuruan tajam penglihatan, rabun 
senja, penyempitan lapang pandang serta seputar anggota keluarga yang menderita 
keluhan yang sama dengan penderita. 
 
2. Kami akan melakukan pemeriksaan : 
a. Tajam penglihatan dengan menggunakan optotipe Snellen, hitung jari, lambaian 
tangan dan sentolop. 
b. Lapang pandang dengan menggunakan tes konfrontasi ataupun Humprey visual 
analysis.. 
c. Funduscopy dengan menggunakan indirek oftalmoskop  
d. Pengambilan darah perifer sebanyak 10 cc dengan menggunakan spuit dan 
dimasukkan dalam tabung yang mengandung EDTA  
3. Keuntungan yang diperoleh penderita : 
- Penderita mengetahui gen penyebab dan sifat penurunannya daripada Retinitis  
pigmentosa yang dideritanya  sehingga kemungkinan penurunan gen tersebut pada 
generasi selanjutnya dapat diketahui. Hal ini sangat penting apabila penderita 
menginginkan keturunan ataupun rencana pernikahan dikemudian hari. 
- Terapi dapat diberikan sesuai dengan jenis mutasinya meski masih terbatas pada   
jenis mutasi tertentu . 
-   Tidak membahayakan penderita 
 
Penyakit Bapak/Ibu akan dirahasiakan dan rahasia akan kami jaga atas seluruh data penelitian 
ini. 
                            Nama              : A Kentar Arimadyo Sulakso 
    Alamat/ HP     : Jl. Bukit Barisan Perum Permata Puri Ngaliyan 50189, 
Semarang / 08886532130  
Kalau Bapak/ Ibu tidak bersedia ikut dalam penelitian ini, Bapak/ Ibu bebas menolak. Atau 
apabila Bapak/ Ibu menghendaki mengundurkan diri dari penelitian ini, kami akan menghormati 
keinginan tersebut. 
 






Setelah mendengar dan memahami penjelasan penelitian , dengan ini saya menyatakan  
SETUJU/ TIDAK SETUJU 
Untuk ikut sebagai responder/ sampel penelitian. 





(…………………………………..)                               (…………………………………..)                                        
 
Alamat :                                                                                               Alamat : 
Telp      :                                                                                              Telp      : 
Tanggal Pemeriksaan :                                                                        No. Pasien : 



























                                                                       




1.   No. Register      :                                   Alamat Rumah  : 
2.   Nama             :                                   No. Telp        : 
3.   Jenis Kelamin    : 
4.   Umur             : 
5.   Pendidikan        : 
6.   Pekerjaan    : 
7.   Kapan mulai timbulnya penurunan tajam penglihatan   : 
8.   Kapan mulai timbulnya rabun senja : 
9.   Kapan penyakit yang diderita di diagnosis sebagai RP :  
10  Apakah ada saudara lain yang menderita penyakit seperti ini? Sebutkan  
11  Apakah ada pernikahan antar saudara dekat?  
                  
                             
       
Pemeriksaan :    


























































DNA was isolated with a salt saturation method as follow: 
EDTA frozen blood was transferred into a 50 mL tube. NH4CL 5-10 ml lysis buffer was added 
to the tube and incubated for 10 - 30 minutes at room temperature. Then the tube was centrifuged 
for 5 minutes at 3000 -3500 RPM, the supernatant was removed and NH4CL lysis buffer was 
added again. These steps were repeated three times. Two milliliters of TE lysis buffer, 
Proteinase-K 10 mg/mL and 100 ul 10% SDS were added and mixed gently into a white pellet 
and then incubated at 50 degree Celsius for 24 hours. Subsequently NaCl 6M approximately one 
third volume of the tube was added to the suspension and centrifuged at 4000 RPM for 10 
minutes. New tubes were used for the supernatant and absolute ethanol twice volume supernatant 
was added. DNA that looked like white substance was removed by fine needle. After that, DNA 
was rinsed with 70% ethanol and transferred into a 1,5 ml tube. Excess ethanol was evaporated 
by leaving the tube open for at least 1 hour. Then the DNA was dissolved into TE buffer 
 
